Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Brian T. Hill, MD, Deepa Jagadeesh, MDMPH, Alex V. Mejia Garcia, MD, Robert M. Dean, MD, Omer N. Koc, MD, Matt Kalaycio, MD, Kirsten M Boughan, DO, Brenda W. Cooper, MD, Allison M. Winter, MD, Wesam B. Ahmed, MD, Brad Pohlman, MD, Christopher D'Andrea, PA-C, Kelsey Holkovic, RN, Ashley Morrison, RN, Paolo Caimi, MD, Mitchell Smith, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-136370

Published: 2020

Journal Articles

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-137235

Published: 2020

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

James R. Berenson, MD, Ralph Vincent Boccia, MD, Asad Bashey, MD PhD, Alexandra M. Levine, MD, Omer N. Koc, MD, Jennifer A. Callahan, Andrew P. Mazar, PhD, Steven D. Reich, MD

Blood (2006) 108 (11): 2593.

https://doi.org/10.1182/blood.V108.11.2593.2593

Published: 2006

Journal Articles

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, PhD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Teresa Melink, NP, Song Liu, John Bender, PharmD

Blood (2006) 108 (11): 691.

https://doi.org/10.1182/blood.V108.11.691.691

Published: 2006

Journal Articles

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Steven Grant, Judith E. Karp, Omer N. Koc, Brenda Cooper, Selina Luger, William D. Figg, Merrill Egorin, Brian J. Druker, James W. Jacobberger, Viswanathan Ramakrishnan, Edward B. Perkins, A. Dimitrios Colevas, John D. Roberts

Blood (2005) 106 (11): 1102.

https://doi.org/10.1182/blood.V106.11.1102.1102

Published: 2005

Journal Articles

Toll-Like Receptor Agonists Induce Secretion of Immunomodulatory Soluble Factors from Human Mesenchymal Stem Cells.

Jeffery J. Auletta, MD, Basabi Maitra, BS, Emese Szekely, BS, Omer N. Koc, MD

Blood (2005) 106 (11): 1394.

https://doi.org/10.1182/blood.V106.11.1394.1394

Published: 2005

Journal Articles

Cellular Expression of CD23, CD71, and CD38 Are Independent Prognostic Variables in B-Cell Chronic Lymphocytic Leukemia.

Howard J. Meyerson, MD, Samir M. Dalia, BA, Omer N. Koc, MD, Pingfu Fu, PhD, Amy E. Cocco, MD

Blood (2004) 104 (11): 2801.

https://doi.org/10.1182/blood.V104.11.2801.2801

Published: 2004

Journal Articles

Peritransplant Use of Ultraviolet-B (UVB) Phototherapy Is Detrimental to Outcome of Allogeneic Stem Cell Transplantation.

Meltem Yuksel, MD, Elma Baron, MD, Brenda W. Cooper, MD, Hillard M. Lazarus, MD, Stanton L. Gerson, MD, Mary J. Laughlin, MD, Kevin D. Cooper, MD, Anita Gilliam, MD, Omer N. Koc, MD

Blood (2004) 104 (11): 1843.

https://doi.org/10.1182/blood.V104.11.1843.1843

Published: 2004

Journal Articles

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, John F. Bender, PharmD

Blood (2004) 104 (11): 587.

https://doi.org/10.1182/blood.V104.11.587.587

Published: 2004

Journal Articles

Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival (DSF) of Relapsed/Refractory Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Hematopoietic Stem Cell Transplant (AHSCT).

Pingfu Fu, PhD, Willem J. Van Heeckeren, MD, Punit D. Wadhwa, MD, David J. Bajor, Richard J. Creger, Phar D, Brenda W. Cooper, MD, Mary J. Laughlin, MD, Hillard M. Lazarus, MD, Stanton L. Gerson, MD, Omer N. Koc, MD

Blood (2004) 104 (11): 917.

https://doi.org/10.1182/blood.V104.11.917.917

Published: 2004

NARROW

Results of a Phase I Trial of Lenalidomide, Rituximab (R 2 ) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma

Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients (pts) with Advanced Hematologic Malignancies.

Active Immunotherapy with FavId® (Id/KLH) Following Rituximab Induction: Long-Term Follow-Up of Response Rate Improvement (RRI) and Disease Progression in Follicular Lymphoma Patients (pts).

Phase I Study of Flavopiridol in Combination with Imatinib Mesylate (STI571, Gleevec) in Bcr/Abl+ Hematological Malignancies.

Toll-Like Receptor Agonists Induce Secretion of Immunomodulatory Soluble Factors from Human Mesenchymal Stem Cells.

Cellular Expression of CD23, CD71, and CD38 Are Independent Prognostic Variables in B-Cell Chronic Lymphocytic Leukemia.

Peritransplant Use of Ultraviolet-B (UVB) Phototherapy Is Detrimental to Outcome of Allogeneic Stem Cell Transplantation.

Id/KLH Vaccine (FavId™) Following Treatment with Rituximab: An Analysis of Response Rate Improvement (RRI) and Time-to-Progression (TTP) in Follicular Lymphoma (FL).

Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival (DSF) of Relapsed/Refractory Patients Treated with High-Dose Chemotherapy (HDC) Plus Autologous Hematopoietic Stem Cell Transplant (AHSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only